GenServe.AI Launches GENIE™-CV
to Support Cardio-metabolic Care

New Orleans, LA – March 30th, 2026

GenServe.AI Launches GENIE-CV to Support Autonomous Cardiometabolic with Voice AI and Close Gaps in Guideline Based Therapy, at Scale

GenServe.AI will be building evidence with leading cardiac centers and health care organizations and expand GENIE-CV nationally through outcome-based risk-sharing contracts and CMS ACCESS program

New Orleans, LA – March 30th, 2026

GenServe.AI, the healthcare-first vendor-agnostic platform for autonomous and clinical AI, today announced the launch of GENIE-CV, a dedicated cardiometabolic agentic and voice AI studio designed to help health systems identify, engage, and longitudinally manage patients with cardiovascular disease and obesity.  GENIE-CV will be offered with outcomes-based payment starting with CMS ACCESS Model,  signaling a new approach for how care organizations can unify fragmented AI investments into a single engine for care delivery, without increasing staffing cost.

Timed to coincide with the American College of Cardiology Annual Meeting, the launch unites FusionCare.AI’s cardiometabolic protocols and monitoring expertise with GenServe.AI’s enterprise governance and orchestration engine, GENIE. Cardiometabolic conditions,  including heart disease, diabetes, hypertension, and obesity,  affect 1 in 2 Americans and represent the single largest driver of preventable hospitalizations, readmissions, and specialty care utilization in the U.S. Health systems have responded by deploying a patchwork of point solutions: remote monitoring tools, patient engagement apps, care coordination software, and EHR-embedded analytics,  each operating in isolation, each requiring separate workflows, and none connecting the clinical dots at population scale. The result is a fragmented care experience for patients and an operational burden for already stretched clinical teams. The timing reflects a major shift in cardiometabolic care delivery. As the use of GLP-1, SGLT2, PCSK9 inhibitors and newer interventions continue to advance, more patients than ever can benefit from evidence-based treatment across obesity and cardiometabolic disease. 

“Demand for obesity and cardiometabolic care is accelerating, while the workforce is stretched and the evidence to transformation gap is widening,” said Dr. Pankaj Rajvanshi, CEO of FusionCare.AI. 

“As nation’s first obesity MSO,  Fusioncare’s goal  has been to offload busy practitioners in optimizing guideline-based care, in between visits. Becoming a part of GenServe.AI’s larger family will now allow us to scale  to entire populations, while supporting reimbursable pathways like CMS ACCESS Model ”

GENIE (Governed Engine for Networked Intelligent Agents) addresses this challenge directly. Unlike traditional point solutions, GenServe.AI’s GENIE platform serves as a unifying orchestration engine and agentic workforce, seamlessly integrating clinical protocols, third-party tools, proprietary systems, and EHR-derived data into a single, governed, autonomous Voice AI supported workflow. GENIE-CV applies this orchestration layer to cardiometabolic care, enabling health systems to deploy three high-impact agentic capabilities that operate across patient populations simultaneously:

 

  • Agentic Care Gap Identification: GENIE-CV continuously analyzes EHR-derived data across entire patient populations to identify gaps in evidence-based, guideline-directed medical therapy, autonomously triggering referrals and outreach before conditions escalate,  at a scale no care coordinator team could achieve manually
  • Agentic Navigation for Pre- and Post-Operative Care: Coordinated, multimodal care pathways using voice and AI-driven engagement guide patients through peri-operative and post-operative journeys, enhancing top line revenue growth for cardiac centers while reducing avoidable readmissions and closing follow-up gaps that today fall through the cracks between clinical handoffs
  • Agentic Condition Monitoring and Transitions of Care: Continuous, autonomous patient monitoring integrated with CMS ACCESS and value-based care program requirements keeps high-risk cardiometabolic patients connected to their care teams between visits, without increases in staffing cost
 
The net effect is equipping health systems, ACOs or health plans with an autonomous operating system that can categorically do more with what it already has: existing technology investments, existing clinical teams, and existing infrastructure, unified into a coherent workflow that works around the clock. The CMS ACCESS Model, effective July 1, 2026, creates a direct reimbursement pathway, opening new revenue streams for care organizations that are positioned to act. Those that deploy compliant infrastructure now stand to capture new revenue, reduce avoidable utilization, and demonstrate measurable quality and outcomes improvement.

“Imagine every single patient gets post-transition care and post procedure follow-up. Every patient is screened to identify evidence-based care gaps and is outreached to help address those gaps using voice and multimodal AI. That’s the premise of GENIE-CV  we plan to bring in partnership with leading health systems and associations.” 

Sarthak Kakkar, Co-founder and Chief Technology Officer, GenServe,AI.

 

 Agentic AI must be held to a higher standard than technical performance alone. Meaningful, trustworthy patient care requires systems that are rigorously evaluated, developed under strong quality and risk-management processes, and supported by clear real-world evidence. That is why GenServe.AI is proud to announce a strategic partnership with BlueBridge Technologies, establishing a regulatory, evaluation, and quality infrastructure that can be leveraged by GenServe partners. This framework encompasses design controls, traceability, software lifecycle discipline, and evidence planning aligned with evolving FDA expectations and applicable standards, ensuring that every organization connected to the GenServe platform can deliver credible clinical value.

 

About GenServe.AI

Guided by the needs of the VALID AI network, representing more than 50 health systems, GenServe.AI has fast become the leading platform for deploying vendor-agnostic generative AI that uses the power of multiple large language models (LLM) across healthcare enterprises in a secure, HIPAA-compliant manner. Its enterprise search graph and no-code AI assistants deliver immediate value across clinical, operational, and administrative workflows.
Built by healthcare leaders for healthcare workflows, GENIE now extends GenServe.AI’s horizontal platform with a clinical agentic command center that enables agentic navigation, referrals, orchestration, and monitoring across vertical service lines—including procedures, surgeries, imaging, and transitions of care, while maintaining clinical integrity, regulatory compliance, and human oversight.

With GENIE-CV, GenServe.AI continues to expand its clinical AI portfolio through a platform approach that supports rapid deployment of domain-specific agentic modules, enterprise-grade governance, and measurable performance, positioning the company for scalable growth across health systems, cardiac centers, and health plans as outcomes-driven adoption accelerates. 

About Fusioncare.AI 

FusionCare.AI, incubated within GVX Venture Studio, was the nation’s first MSO (Management Services Organization) that brought “Obesity and Cardiometabolic Care in a Box”- that streamlines care delivery, empowering patients and providers alike. Patients benefit enhanced access before and within clinic visits from tailored treatment pathways and continuous support throughout their health journeys. Providers benefit from better screening and optimization of patients while saving their precious clinical time and generating additional revenue from novel reimbursable pathways. FusionCare.AI will become part of GenServe.AI and its clinical protocol, intelligence and revenue enhancement model will help shape GENIE-CV, an obesity and cardiovascular specific clinical agentic module.

About BlueBridge Technologies

BlueBridge Technologies is the regulatory-engineering partner helping GenServe.AI turn GENIE-CV from a clinical agentic AI platform into an FDA-ready AI-enabled software as a medical device (SaMD). Drawing on a UL-certified ISO 13485 quality management system, ISO 14971 risk management, and IEC 62304 software lifecycle expertise, BlueBridge supports GenServe.AI partners in building the design controls, evidence framework, traceability, and validation approach required for regulatory submission. By helping align product development with evolving FDA expectations and applicable standards, BlueBridge is providing the regulatory and quality foundation needed to scale GENIE-CV fully autonomous use-cases across health care organizations with confidence.

 

To explore a GENIE-CV co-development, outcomes-based partnership or request a CMS ACCESS readiness assessment, contact partner@genserve.ai

As Thanksgiving week comes to a close, we’ve taken time to pause, reflect, and feel immense gratitude for everyone who has been part of GenServe.AI’s journey so far. Our first Thanksgiving as GenServians reminded us just how much we have to be thankful for — the people, partnerships, and shared purpose driving everything we do.

 Over the past year, we’ve pushed boundaries, built innovative healthcare AI tools, and envisioned a future where technology helps clinicians work smarter, patients receive better care, and health systems move toward equity and excellence. But what truly defined this year wasn’t just innovation — it was collaboration.

We’re especially grateful to:

  • Clinicians, Partners, and Health-System Leaders: Your insight and trust helped us shape technology that meets real clinical needs and supports the people at the heart of care delivery.
  • Collaborators, Advisors, Investors, and Believers: Your guidance and encouragement strengthened our vision and kept us focused on impact.
  • Our Team: Every GenServian’s commitment and creativity turned bold ideas into real progress. You’ve powered nights of coding, conversations with providers, and moments of discovery that continue to move us forward.
Thanks to this collective effort, we’re now live in health systems across the country and advancing our vision through the #AICentersofExcellenceNetwork — helping bring AI-enabled care closer to reality.
As we return from the holiday rest, we carry this sense of gratitude into the season ahead. We’re energized to keep building, partnering, and pioneering, knowing how much we can achieve together.
From all of us at GenServe.AI — thank you for being part of our journey. Here’s to closing the year with gratitude and growth.